Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • ORAL FORMULATION
    Publication number: 20170202833
    Abstract: Provided are an oral formulation capable of improving easy administrability and showing good preservation stability, and a substrate for oral formulation. An oral formulation containing a medicament; sugar alcohol; one or more kinds of hydrophilic polysaccharides selected from the group consisting of acacia, pullulan and maltodextrin; a gelling agent; and water, and a substrate for oral formulation, which contains sugar alcohol; the above-mentioned hydrophilic polysaccharides; a gelling agent; and water.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Taro IWAMOTO, Nobuyuki KURAHASHI, Yoshikazu OKA, Chikako TAKEDA
  • Method and apparatus for manufacturing nucleated tablets
    Patent number: 9707729
    Abstract: Provided is a method and apparatus for manufacturing nucleated tablets in each of which a nucleus is positioned in a precise manner. In the tablet manufacturing machine (1), granules are charged in a mortar and then compressed by pestles while the mortar and the pestles travel along a cyclic path extending from a point and then back to the point. The path has a substantially straight path portion where the mortar and the pestles travel substantially straightly.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: July 18, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Hiroshi Inaka
  • Cyanopyrimidine derivative
    Patent number: 9708292
    Abstract: The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: July 18, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Norifumi Sato, Yohei Yuki, Hisashi Shinohara, Yasuhiro Takeji, Kuni Ito, Daisaku Michikami, Keisuke Hino, Hiroyuki Yamazaki
  • DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE
    Publication number: 20170196877
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki FUJIKI, Miki AIHARA, Shizuo KINOSHITA
  • ENERGY MALNUTRITION EVALUATION FOR LIVER DISEASE TEST SUBJECT
    Publication number: 20170199172
    Abstract: A method for measuring energy malnutrition in a liver disease test subject, a method for determining whether a liver disease test subject is in an energy malnutrition state, a method for determining the necessity of nutrition therapy for a liver disease test subject having energy malnutrition, a composition usable in these methods, and the like are provided. The method for measuring energy malnutrition in a liver disease test subject includes the steps of collecting expired air containing labeled carbon dioxide that is generated in the body of a liver disease test subject by being converted from a composition containing, as an active ingredient, glucose labeled with at least one isotope C; and determining the ratio of labeled CO2 amount to unlabeled CO2 amount, or the ratio of labeled CO2 amount to total CO2 amount in expired air.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Makoto INADA, Jun-ichi KUNIZAKI, Kazuki TOBITA
  • PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS
    Publication number: 20170198293
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 13, 2017
    Applicants: Mie University, Otsuka Pharmaceutical Co., Ltd.
    Inventors: Esteban C. GABAZZA, Tetsu KOBAYASHI, Hidekazu TOYOBUKU, Ayako FUKUDA, Tetsuya HASEGAWA
  • Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
    Patent number: 9694009
    Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: July 4, 2017
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • MEDICAL TABLET, AND MANUFACTURING METHOD AND MANUFACTURING APPARATUS FOR MEDICAL TABLET
    Publication number: 20170181969
    Abstract: An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of being positioned above pharmaceutical powder filled in a die hole before compression. The IC chip is supplied by a pusher.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 29, 2017
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., OMORI MACHINERY CO., LTD.
    Inventors: Etsuhiro MAEDA, Yasutoshi KOHATA
  • N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS
    Publication number: 20170166524
    Abstract: The present invention provides a pyrrolidine compound of General Formula (1) or a salt thereof, wherein R101 and R102 are each independently a phenyl group or a pyridyl group, the phenyl group or the pyridyl group may have one or more substituents selected from halogen atoms and lower alkyl groups optionally substituted with one or more halogen atoms, etc. The pyrrolidine compound or a salt thereof of the present invention is usable to produce a pharmaceutical preparation having a wider therapeutic spectrum and being capable of exhibiting sufficient therapeutic effects after short-term administration.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 15, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Muneaki KURIMURA, Shinichi TAIRA, Takahiro TOMOYASU, Nobuaki ITO, Kuninori TAI, Noriaki TAKEMURA, Takayuki MATSUZAKI, Yasuhiro MENJO, Shin MIYAMURA, Yohji SAKURAI, Akihito WATANABE, Yasuyo SAKATA, Takumi MASUMOTO, Kohei AKAZAWA, Haruhiko SUGINO, Naoki AMADA, Satoshi OHASHI, Tomoichi SHINOHARA, Hirofumi SASAKI, Chisako MORITA, Junko YAMASHITA, Satoko NAKAJIMA
  • TABLET COMPRISING 7-[4-(4-BENZO[B]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR A SALT THEREOF
    Publication number: 20170165258
    Abstract: This invention relates to a tablet containing, as an active ingredient, 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, that has excellent disintegration ability, storage stability and photostability. The tablet of the present invention comprising an uncoated tablet containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof as an active ingredient, excipients such as lactose, corn starch, and microcrystalline cellulose; disintegrants such as low-substituted hydroxypropylcellulose, croscarmellose sodium, and sodium carboxymethyl starch; binders such as hydroxypropylcellulose; lubricants such as stearate; and further comprising a coating layer containing hypromellose; talc; titanium oxide; colorant; and the like, the coating layer being applied to the surface of the uncoated tablet.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Yoshiharu INOUE
  • Drug for preventing and/or treating polycystic kidney disease
    Patent number: 9669075
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: June 6, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • PHARMACEUTICAL PREPARATION COMPRISING BREXPIPRAZOLE AND SUBSTITUTED BETA-CYCLODEXTRIN
    Publication number: 20170151237
    Abstract: Provided is an aqueous pharmaceutical preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (compound (I)) or a salt thereof, which shows improved water solubility of compound (I) or a salt thereof achieved by addition of substituted ?-cyclodextrin. The present invention provides a pharmaceutical preparation comprising compound (I) or a salt thereof, and substituted ?-cyclodextrin.
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuya HASEGAWA, Hidekazu TOYOBUKU
  • NOVEL LACTOBACILLUS PARACASEI STRAIN
    Publication number: 20170137902
    Abstract: A major object of the present invention is to provide an effective means for promoting polyamine synthesis in an organism (in particular, in humans). Lactobacillus paracasei having polyamine production promoting activity in an organism.
    Type: Application
    Filed: March 23, 2015
    Publication date: May 18, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi IKENAGA, Tsuneyuki NODA, Yoshito TAJIRI, Hiroki NOGUCHI, Atsushi UEDA, Noriyuki KOUDA
  • ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE
    Publication number: 20170136010
    Abstract: [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD
    Inventors: Haruka YOSHIDA, Toshiaki TANIGUCHI, Tadashi MUKAI
  • METHOD FOR MEASURING ANTI-WT1 ANTIBODY
    Publication number: 20170138958
    Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.
    Type: Application
    Filed: December 8, 2016
    Publication date: May 18, 2017
    Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Haruo SUGIYAMA, Yusuke OJI, Kiyonori KATSURAGI, Hideaki TANAKA, Shinji SOGO, Yoshihiro GOTO, Yasukazu OHMOTO, Husako IWATA
  • Drug for preventing and/or treating polycystic kidney disease
    Patent number: 9636382
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: May 2, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Preventive or therapeutic agent for fibrosis
    Patent number: 9637743
    Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: May 2, 2017
    Assignees: MIE UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Esteban C Gabazza, Tetsu Kobayashi, Hidekazu Toyobuku, Ayako Fukuda, Tetsuya Hasegawa
  • Therapeutic compounds and related methods of use
    Patent number: 9630947
    Abstract: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP), such as those of formula (III), and composition thereof are described herein. Exemplary disorders include schizophrenia and cognitive deficit.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: April 25, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahashi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimizu, Kevin J. Hodgetts, Jason S. Newcom
  • Agent for improving or maintaining QOL
    Patent number: 9623054
    Abstract: An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. [Method for Achieving the Object] A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: April 18, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mina Tsubouchi, Takao Saito, Masamichi Toba, Noriyuki Kouda, Shoji Shinkai
  • COMBINATIONS COMPRISING BREXPIPRAZOLE OR A SALT THEREOF AND A SECOND DRUG FOR USE IN THE TREATMENT OF A CNS DISORDER
    Publication number: 20170100395
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA